TRVINasdaqPharmaceutical PreparationsFiscal year ends December 31
Trevi Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$11.90+0.02 (+0.17%)
Close on Oct 19, 2026
- Market cap
- $1.86B
- P/E (TTM)
- –
- Dividend yield
- –
Share price
+$1.54 (+14.86%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $1.86B
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 5.80
- Dividend yield
- –
- Free cash flow yield
- -2.84%
Fundamentals
- Net income
- -$51.11M
- EPS, diluted
- -$0.34
- Free cash flow
- -$52.87M
- Book value per share
- $2.05
- Diluted shares
- 157M
Nine years at a glance
Fiscal years 2017 to 2025 and trailing twelve months, USD
Operating income
-$59.56M
Net income
-$51.11M
EPS, diluted
-$0.34
Free cash flow
-$52.87M
Reported periodTrailing twelve months